Sign In
Buy BIO
$301.70
-0.200 (-0.0662%)
At Close: Jul 21, 2026
Cooper Companies (COO) to Post Q2 Earnings: What's in Store?
02:03pm, Thursday, 26'th May 2022 Zacks Investment Research
Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.
Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?
02:48pm, Wednesday, 25'th May 2022 Zacks Investment Research
Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect a solid show by its segments and robust product portfolio.
Wall Street Analysts Believe Bio-Rad (BIO) Could Rally 53%: Here's is How to Trade
01:55pm, Wednesday, 25'th May 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positiv
If You Invested $1000 in Bio-Rad Laboratories 10 Years Ago, This Is How Much You'd Have Now
12:30pm, Wednesday, 25'th May 2022 Zacks Investment Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Wall Street Analysts Believe Bio-Rad (BIO) Could Rally 53%: Here's is How to Trade
11:33am, Wednesday, 25'th May 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positiv
15 stocks that have fallen at least 33% but by these measures are still standouts in their sectors
10:25am, Tuesday, 17'th May 2022 MarketWatch
Signature Bank, Nvidia, Salesforce and 12 other companies may be oversold, based on expectations for earnings and sales growth in 2023.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up
02:31pm, Friday, 29'th Apr 2022 Zacks Investment Research
Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up
12:02pm, Friday, 29'th Apr 2022
Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.
Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q1 2022 Results - Earnings Call Transcript
11:03pm, Thursday, 28'th Apr 2022
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2022 Earnings Conference Call April 28, 2022 6:00 PM ET Company Participants Ed Chung - Head of Investor Relations Ilan Daskal - Executive Vice President & Ch
Bio-Rad Laboratories (BIO) Surpasses Q1 Earnings and Revenue Estimates
09:45pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Bio-Rad (BIO) delivered earnings and revenue surprises of 76.43% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Laboratories (BIO) Surpasses Q1 Earnings and Revenue Estimates
06:48pm, Thursday, 28'th Apr 2022
Bio-Rad (BIO) delivered earnings and revenue surprises of 76.43% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More
02:52pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.
Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More
12:18pm, Wednesday, 27'th Apr 2022
Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.
Bio-Rad (BIO) to Report Q1 Earnings: What's in the Cards?
01:02pm, Monday, 25'th Apr 2022 Zacks Investment Research
Robust uptake of dPCR products and a rebound in routine testing are likely to have contributed to Bio-Rad's (BIO) first-quarter top line.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
02:19pm, Tuesday, 19'th Apr 2022 Zacks Investment Research
Investors are optimistic about Bio-Rad (BIO) owing to a recovery in most of its key global markets as well as an uptick in demand for COVID-related products.
